Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 24, 2014, 108 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $3.42 to $10,356,964.00.

Highlighted Stocks Traded by Insiders:

Fairchild Semiconductor International (FCS) - FREE Research Report

Carinalli Charles, who is Director at Fairchild Semiconductor International, sold 8,000 shares at $15.76 on Nov. 24, 2014. Following this transaction, the Director owned 36,000 shares meaning that the stake was reduced by 18.18% with the 8,000-share transaction.

The shares most recently traded at $16.27, up $0.51, or 3.13% since the insider transaction. Historical insider transactions for Fairchild Semiconductor International go as follows:

  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 16,100
  • 24-Week # shares bought: 20,000
  • 24-Week # shares sold: 16,100

The average volume for Fairchild Semiconductor International has been 1.9 million shares per day over the past 30 days. Fairchild Semiconductor International has a market cap of $1.9 billion and is part of the technology sector and electronics industry. Shares are up 21.35% year-to-date as of the close of trading on Monday.

Fairchild Semiconductor International, Inc. designs, develops, manufactures, and sells power analog, power discrete, and non-power semiconductor solutions worldwide. The company has a P/E ratio of 226.9. Currently, there is 1 analyst who rates Fairchild Semiconductor International a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FCS - FREE

TheStreet Quant Ratings rates Fairchild Semiconductor International as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Fairchild Semiconductor International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Green Dot (GDOT) - FREE Research Report

Wang Grace, who is Chief Financial Officer at Green Dot, sold 8,000 shares at $22.42 on Nov. 24, 2014. Following this transaction, the Chief Financial Officer owned 109,942 shares meaning that the stake was reduced by 6.78% with the 8,000-share transaction.

The shares most recently traded at $22.34, down $0.08, or 0.36% since the insider transaction. Historical insider transactions for Green Dot go as follows:

  • 4-Week # shares sold: 69,368
  • 12-Week # shares sold: 69,368
  • 24-Week # shares sold: 69,368

The average volume for Green Dot has been 469,900 shares per day over the past 30 days. Green Dot has a market cap of $1.0 billion and is part of the financial sector and financial services industry. Shares are down 11.69% year-to-date as of the close of trading on Monday.

Green Dot Corporation, together with its subsidiaries, operates as a technology-centric, pro-consumer bank holding company that provides personal banking for the masses. The company has a P/E ratio of 22.9. Currently, there are 4 analysts who rate Green Dot a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GDOT - FREE

TheStreet Quant Ratings rates Green Dot as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Green Dot Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Merrimack Pharmaceuticals (MACK) - FREE Research Report

Porter Michael E, who is Director at Merrimack Pharmaceuticals, bought 11,909 shares at $8.87 on Nov. 24, 2014. Following this transaction, the Director owned 625,164 shares meaning that the stake was boosted by 1.94% with the 11,909-share transaction.

The shares most recently traded at $9.51, up $0.64, or 6.68% since the insider transaction. Historical insider transactions for Merrimack Pharmaceuticals go as follows:

  • 4-Week # shares bought: 45,000
  • 12-Week # shares bought: 45,000
  • 24-Week # shares bought: 77,390

The average volume for Merrimack Pharmaceuticals has been 2.2 million shares per day over the past 30 days. Merrimack Pharmaceuticals has a market cap of $956.1 million and is part of the health care sector and drugs industry. Shares are up 72.76% year-to-date as of the close of trading on Monday.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Currently, there are 3 analysts who rate Merrimack Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MACK - FREE

TheStreet Quant Ratings rates Merrimack Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its unimpressive growth in net income. Get the full Merrimack Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null